The regulatory status of NAD+ and its precursors has changed several times in recent years and continues to evolve. This article reflects the most up-to-date verified information available at the time of its preparation. Because the situation in this area can change rapidly, the legal status is best considered on a country-by-country or region-by-region basis and always with respect to a specific point in time, particularly when purchasing, prescribing, importing, or selling NAD+-related products.
Can NAD+ be legally purchased and used?
NAD+ and its most commonly used precursors are not classified as controlled substances in the United States, the European Union, or the United Kingdom, which is why simply possessing them is generally legal.
Legal possession and legal sale are, however, separate regulatory issues. Whether a given product can be legally placed on the market depends on the specific compound, formulation, intended use, and jurisdiction.
Oral nicotinamide riboside, or NR, currently has the most transparent regulatory status among the major NAD+ precursors.
In the United States, NR, sold as Niagen by Niagen Bioscience, formerly ChromaDex, holds self-affirmed Generally Recognized as Safe status and has received positive New Dietary Ingredient notifications from the FDA. This allows qualifying products containing NR to be marketed as dietary supplements in accordance with applicable US requirements [1].
In the European Union, NR received a positive safety opinion from the European Food Safety Authority in 2019. It subsequently obtained authorization as a Novel Food, which allows the sale of products containing NR in EU member states, provided they meet the approved conditions and specifications [2].
Oral NMN has had a much less stable regulatory history, particularly in the United States. Its status has changed significantly over the past few years and is discussed separately below.
Niacin and nicotinamide, which are the standard forms of vitamin B3, have a much longer and better-established regulatory history. Both substances are widely used as dietary supplements and food fortification ingredients in the US, EU, and UK.
Injectable and intravenous NAD+ fall into a different regulatory category. These products are not regulated like standard consumer dietary supplements and in the United States are typically provided as compounded pharmaceutical preparations.
Does NAD+ require a prescription?
Prescription requirements depend primarily on the product's form and its regulatory category.
Oral NAD+ precursor supplements, including NR and currently NMN in the United States, generally do not require a prescription as long as they are legally marketed as dietary supplements and meet applicable regulatory requirements.
The situation is different in the case of injectable and intravenous NAD+.
NAD+ has not been approved by the FDA as a drug for any indication, and there is no FDA-approved injectable NAD+ product sold as a standard prescription or over-the-counter medicine.
Injectable and intravenous NAD+ products available in some clinics, telemedicine services, and pharmacies are typically compounded preparations rather than FDA-approved standardized drugs [3].
In the United States, these products may be prepared by state-licensed 503A pharmacies or by 503B outsourcing facilities.
503A compounding pharmacies typically prepare medications for specific patients based on valid prescriptions. In contrast, 503B facilities may produce larger batches of products under a different regulatory framework and with additional federal oversight.
Because compounded injectable medications are provided within the medical and prescription system, access to injectable or intravenous NAD+ in the United States typically requires a prescription or order from a licensed healthcare practitioner.
This regulatory status should not be confused with FDA approval. The compounding NAD+ product can be legally prepared and prescribed in accordance with applicable pharmacy compounding rules without having FDA-approved drug status.
What is the FDA's current stance on compounded NAD+ injections?
The regulatory status of compounded NAD+ injections has evolved significantly in recent years.
NAD+ alone has never been approved by the FDA as a drug for any indication, and there is currently no FDA-approved injectable NAD+ product available. Injectable and intravenous NAD+ products provided by clinics or compounding pharmacies are therefore compounded preparations, not approved drugs [3].
The FDA has also taken specific enforcement and safety actions regarding prescription NAD+ products.
In 2024, the agency reminded compounding pharmacies that NAD+ used in sterile injectable preparations must be of pharmaceutical grade and sourced appropriately. Food-grade or research-grade NAD+ was not considered suitable for use in sterile compounded injectable preparations [4].
A more serious safety event occurred in October 2025, when the FDA identified a Class I recall of a prescription NAD+ injection product due to bacterial endotoxin contamination [4].
A Class I recall is the most serious category of FDA recall and is used when there is a reasonable probability that exposure to a product will cause serious health consequences or death.
Following the product recall in January 2026, the FDA issued a warning letter to the manufacturer, citing violations of federal drug manufacturing requirements applicable to outsourcing facilities [4].
These actions concern the quality and manufacturing method of compounded NAD+ injection products, rather than a statement that NAD+ itself is categorically banned.
NMN has undergone a separate and particularly complex regulatory path.
In November 2022, the FDA determined that NMN is excluded from the legal definition of a dietary supplement under federal law concerning ingredients previously authorized for investigation as new drugs [5].
The Agency based this decision on the Investigational New Drug application for the NMN-related drug candidate MIB-626, considering that it was authorized for clinical trials before NMN was lawfully marketed as a dietary supplement.
This decision caused significant disruption in the US supplement market, including the removal of NMN products from several major sales platforms.
Following legal challenges and industry petitions, the FDA reversed its position in September 2025 and acknowledged that NMN is not excluded from the definition of a dietary supplement [5].
The agency then directly confirmed this position to ingredient suppliers in December 2025.
According to the current regulatory position described here, NMN may once again be legally marketed in the United States as a dietary supplement, provided that other applicable supplement requirements are met.
The rapid shift from exclusion in 2022 to a reversal of position in 2025 shows how quickly the regulatory status of NAD+-related compounds can change.
Is NAD+ banned in sports or specific professional environments according to WADA?
NAD+ alone does not appear by name on the current World Anti-Doping Agency's Prohibited List of Substances and Methods [6].
Intravenous administration, however, introduces a separate anti-doping issue.
According to WADA category M2.2 on chemical and physical manipulation, intravenous infusions or injections exceeding a total volume of 100 ml per 12-hour period are prohibited regardless of the substance administered [7].
Exceptions include situations where the infusion is legally used during hospital treatment, a surgical procedure, or a clinical diagnostic study.
This means that the anti-doping issue may concern the route of administration, not NAD+ itself.
Session IV NAD+ involving more than 100 ml within 12 hours may therefore be subject to the prohibition on the method of administration for an athlete governed by WADA regulations, even though NAD+ itself is not separately listed as a prohibited substance.
Similar restrictions on IV infusion volumes have led to sanctions in other sports situations when athletes received standard intravenous fluids without realizing that the administration method itself was restricted [7].
Oral NR, NMN, niacin, and nicotinamide are not subject to this specific intravenous infusion volume restriction because they are not administered via IV infusion.
The anti-doping status remains subject to current regulations, as the WADA Prohibited List is updated annually. Anti-doping organizations of individual sports disciplines may also publish additional interpretations or requirements.
How do regulations differ in the UK and EU compared to the United States?
Regulatory requirements vary significantly between the United States, the European Union, and the United Kingdom.
FDA regulations apply exclusively to the US market and do not determine whether a given product can be legally sold in the EU or the UK. Each jurisdiction operates on the basis of its own laws, authorization procedures, and law enforcement systems.
In the European Union, novel foods are subject to the Novel Food Regulation (EU) 2015/2283.
An ingredient without a significant history of consumption as food in the EU before May 1997 generally requires special authorization before it can be legally placed on the market as food or a dietary supplement.
NR underwent this process after receiving a positive EFSA safety assessment in 2019. It was subsequently authorized as a Novel Food, enabling the sale of compliant NR products in EU member states within the approved specifications [2].
NMN is in a different situation.
EFSA issued a positive safety opinion on NMN in May 2026, stating that the consumption of up to 300 mg per day is safe for adults, excluding pregnant and breastfeeding women [8].
However, a positive EFSA opinion is not in itself a final authorization to place the product on the market.
The formal Novel Food authorization still requires the completion of the procedure conducted by the European Commission, along with the relevant stages involving EU member states.
Until this process is completed, NMN does not have the same finalized Novel Food authorization status in the EU as NR.
In practice, NMN products continue to appear on the European market, and this situation is often described in industry publications as a regulatory grey area while awaiting final authorization.
Post-Brexit Great Britain operates within a separate system.
Great Britain, comprising England, Scotland and Wales, operates its own Novel Food authorization process administered by the Food Standards Agency.
Although the British and EU systems are based on similar principles, authorization in one jurisdiction does not mean automatic authorization in the other.
According to the regulatory status described here, NMN has not received final Novel Food authorization in the UK [9].
Nevertheless, the products remain widely available on the market, creating a discrepancy between their formal authorization status and their actual commercial availability.
Therefore, the overall regulatory landscape is heavily dependent on the jurisdiction.
NR has a relatively established status in the United States and the European Union.
NMN currently holds status allowing it to be legally marketed as a dietary supplement in the United States following the FDA's shift in stance in 2025, while its formal Novel Food status remains less definitively resolved in the EU and the UK.
Injectable and intravenous NAD+ are subject to separate medical and compounding frameworks and should not be considered equivalent to orally sold supplements.
Limitations of this information
- The regulatory status of NAD+ and its precursors, especially NMN, has changed several times in a short period and may still change.
- The information summarized here reflects the most up-to-date verified status available at the time the article was prepared, rather than a permanent legal classification.
- The legal status may vary depending on the compound, formulation, route of administration, intended use, labeling, method of production, and jurisdiction.
- The article summarizes regulatory information and enforcement actions from government agency press releases and contemporary industry or news publications rather than peer-reviewed clinical studies, which is appropriate for a question concerning legal and regulatory status.
- The FDA's position pertains to the United States and does not determine the regulatory status in the European Union or the United Kingdom.
- A positive scientific opinion from EFSA does not automatically mean final Novel Food authorization by the European Commission.
- Commercial availability does not necessarily mean that the product has undergone all required regulatory procedures.
- Legal compounding of an injectable product does not mean the product has gained FDA approval as a drug.
- The WADA Prohibited List of Substances and Methods and related guidelines are regularly updated, so anti-doping classification and route of administration restrictions may change over time.
- The enforcement of dietary supplement and Novel Food regulations can vary in practice between individual EU member states, British authorities, and US states, even when broader federal or regional frameworks are in place.
Disclaimer
The article is for general educational purposes only and is a summary of regulatory information. It is not legal, regulatory, medical, prescription, import, or business advice.
The legal status of NAD+, NR, NMN, and related products varies depending on the jurisdiction, formulation, route of administration, intended use, labeling, and current regulatory decisions.
Regulatory classifications can change, especially in the case of newer ingredients such as NMN. When legal or regulatory status is relevant to a specific decision, current official information from the FDA, EFSA, European Commission, FSA, MHRA, WADA, or other competent authorities should be the overriding source.
NAD+ and its precursors should not be presented as drugs approved by the FDA, EMA, or equivalent regulatory bodies for the treatment, prevention, or cure of diseases, unless referring to a specific approved medicinal product and indication.
Commercial availability, legal possession, dietary supplement status, Novel Food authorization, legal compounding in a pharmacy, and formal approval as a medicinal product are distinct regulatory concepts and should not be treated as equivalent.
References
[1] Niagen Bioscience (formerly ChromaDex). (2016). Generally Recognized as Safe (GRAS) self-affirmation and New Dietary Ingredient notifications for nicotinamide riboside chloride (Niagen). U.S. Food and Drug Administration.
[2] European Food Safety Authority. (2019). Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal.
[3] U.S. Food and Drug Administration. (2024–2026). Compounding and the FDA: Questions and answers; 503A and 503B facility guidance. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding
[4] U.S. Food and Drug Administration. (2025–2026). Recalls, market withdrawals, & safety alerts: Compounded NAD+ injectable products. U.S. Food and Drug Administration. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
[5] U.S. Food and Drug Administration. (2022, November; 2025, September). Constituent update: Nicotinamide mononucleotide (NMN) dietary supplement determination. U.S. Food and Drug Administration. https://www.fda.gov/food/cfsan-constituent-updates
[6] World Anti-Doping Agency. (2026). The 2026 Prohibited List. World Anti-Doping Agency. https://www.wada-ama.org/en/prohibited-list
[7] U.S. Anti-Doping Agency. (2026). IV infusion: Explanatory note. U.S. Anti-Doping Agency. https://www.usada.org/athlete-advisory/iv-infusions-explanatory-note/
[8] European Food Safety Authority. (2026, May). Scientific opinion on the safety of synthetic beta-nicotinamide mononucleotide (β-NMN) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal.
[9] UK Food Standards Agency. (2025–2026). Novel food applications and authorisations register. Food Standards Agency. https://www.food.gov.uk/business-guidance/novel-foods